By Dr Mark William Donoghoe

Journal articles

Ting R; Davis T; Drury P; Donoghoe M; Rajamani K; Best J; Kesaniemi Y; Keech A, 2011, 'Cardiovascular Risk, Renal Status and Fenofibrate Safety in the FIELD Study', Heart, Lung and Circulation, 20, pp. S202 - S202, http://dx.doi.org/10.1016/j.hlc.2011.05.497

Donoghoe MW; Gebski V, 2011, 'Impact of the censoring distribution on time-to-event problems in the presence of competing risks', Trials, 12, http://dx.doi.org/10.1186/1745-6215-12-s1-a140

Rajamani K; Donoghoe M; Li L; Ting R-D; Colman P; Scott R; Laakso M; Keech A, 2010, 'FENOFIBRATE REDUCES PERIPHERAL NEUROPATHY IN TYPE 2 DIABETES: THE FENOFIBRATE INTERVENTION AND EVENT LOWERING IN DIABETES (FIELD) STUDY', ATHEROSCLEROSIS SUPPLEMENTS, 11, pp. 219 - 220, http://dx.doi.org/10.1016/S1567-5688(10)71046-1

Ting R-D; Davis TME; Drury PL; Donoghoe M; Rajamani K; Best JD; Kesaniemi YA; Keech AC, 2010, 'MS544 CARDIOVASCULAR AND RENAL SAFETY OF FENOFIBRATE IN THE FIELD STUDY', Atherosclerosis Supplements, 11, pp. 219 - 219, http://dx.doi.org/10.1016/s1567-5688(10)71044-8

Sullivan D; Donoghoe M; Simes J; George J; Keech T, 2009, 'Abstract: P496 LONG-TERM FENOFIBRATE USE IS ASSOCIATED WITH REDUCED PREVALENCE OF LIVER ENZYME ELEVATION IN THE FIELD STUDY', Atherosclerosis Supplements, 10, pp. e809 - e809, http://dx.doi.org/10.1016/s1567-5688(09)70791-3

Back to profile page